Clinical Trial

A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

Study acronym: ARC-8
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, open-label, dose-escalation, and dose-expansion, with a gated randomization portion, study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and clinical activity of AB680 in combination with zimberelimab (AB122), nab-paclitaxel and gemcitabine in participants with advanced pancreatic cancer.
Protocol Amendment History 1 change
notable Trial sites reduced: 13 -> 9 locations 2026-07-03
Trial Details
NCT Number NCT04104672
Lead Sponsor Arcus Biosciences, Inc.
Conditions Advanced Pancreatic Cancer
Enrollment 196 participants
Start Date 2019-11-06
Primary Completion 2027-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-02